0.511
price down icon8.44%   -0.0471
after-market After Hours: .51 -0.001 -0.20%
loading

Plus Therapeutics Inc Stock (PSTV) Latest News

pulisher
07:53 AM

Plus Therapeutics Sets Earnings Date: CNS Cancer Drug Developer to Report Q4 Results - StockTitan

07:53 AM
pulisher
07:42 AM

Plus Therapeutics, Inc. to Announce Q4 and Full Year 2024 Financial Results on March 27, 2025 - Nasdaq

07:42 AM
pulisher
07:31 AM

Plus Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire

07:31 AM
pulisher
Mar 18, 2025

Plus Therapeutics (NASDAQ:PSTV) Now Covered by Analysts at D. Boral Capital - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

Plus Therapeutics stock gains on Boral Capital Buy rating By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 17, 2025

Plus Therapeutics stock gains on Boral Capital Buy rating - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

D. Boral Capital Initiates Coverage of Plus Therapeutics (PSTV) with Buy Recommendation - Nasdaq

Mar 17, 2025
pulisher
Mar 16, 2025

Plus Therapeutics regains compliance with Nasdaq minimum stockholders’ equity requirement - MSN

Mar 16, 2025
pulisher
Mar 11, 2025

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement - Bluefield Daily Telegraph

Mar 11, 2025
pulisher
Mar 11, 2025

Plus Therapeutics Raises $15M: Strategic Financial Move Includes Debt Conversion - StockTitan

Mar 11, 2025
pulisher
Mar 10, 2025

Plus Therapeutics Regains Nasdaq Compliance - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Plus Therapeutics regains Nasdaq compliance status By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Plus Therapeutics regains Nasdaq compliance - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

SEC Form 424B3 filed by PLUS THERAPEUTICS Inc. - Quantisnow

Mar 10, 2025
pulisher
Mar 10, 2025

Plus Therapeutics regains Nasdaq compliance status - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Plus Therapeutics Regains Compliance With Nasdaq Minimum Stockholders' Equity Requirement - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

Plus Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Plus Therapeutics Secures Future on Nasdaq After Meeting Equity Requirements - StockTitan

Mar 10, 2025
pulisher
Mar 08, 2025

PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy - MSN

Mar 08, 2025
pulisher
Mar 07, 2025

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Insider Monkey

Mar 07, 2025
pulisher
Mar 07, 2025

Plus Therapeutics Announces Peer-Reviewed Publication in - GlobeNewswire

Mar 07, 2025
pulisher
Mar 07, 2025

Plus Therapeutics Continues Rally On FridayHere's Why - Benzinga

Mar 07, 2025
pulisher
Mar 07, 2025

Plus Therapeutics' Brain Cancer Therapy Shows Promise in Early-Stage Study; Shares Rise - Marketscreener.com

Mar 07, 2025
pulisher
Mar 07, 2025

Pre-Hour Momentum Drives Plus Therapeutics (PSTV) Stock Higher On FDA Designation - Stocks Telegraph

Mar 07, 2025
pulisher
Mar 07, 2025

FDA ODD given to Plus Therapeutics’ injectable radiotherapy - Yahoo Finance

Mar 07, 2025
pulisher
Mar 07, 2025

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma - Yahoo Finance

Mar 07, 2025
pulisher
Mar 07, 2025

RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial - Nature.com

Mar 07, 2025
pulisher
Mar 06, 2025

Plus Therapeutics’ $15 Million Private Placement - Global Legal Chronicle

Mar 06, 2025
pulisher
Mar 06, 2025

Pharma Stock Plus Therapeutics, Inc. (Nasdaq: $PSTV) Makes NASDAQ Top Gainer List on FDA News - Investorideas.com newswire

Mar 06, 2025
pulisher
Mar 06, 2025

Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment - MSN

Mar 06, 2025
pulisher
Mar 06, 2025

Plus Therapeutics Gets FDA Orphan Drug Designation for Rhenium Obisbemeda in Lung Cancer; Shares Surge - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Plus Therapeutics stock rises on FDA Orphan tag (PSTV:NASDAQ) - Seeking Alpha

Mar 06, 2025
pulisher
Mar 06, 2025

FDA grants orphan drug status to Plus Therapeutics’ cancer treatment By Investing.com - Investing.com South Africa

Mar 06, 2025
pulisher
Mar 06, 2025

FDA grants orphan drug status to Plus Therapeutics’ cancer treatment - Investing.com

Mar 06, 2025
pulisher
Mar 06, 2025

Plus Therapeutics secures $5.7M to support leptomeningeal metastases program - MSN

Mar 06, 2025
pulisher
Mar 06, 2025

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation For Rhenium (186Re) Obisbemeda - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Plus Therapeutics granted Orphan Drug Designation for Rhenium Obisbemeda - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Can This Rare FDA Designation Transform Plus Therapeutics' Cancer Treatment Future? - StockTitan

Mar 06, 2025
pulisher
Mar 05, 2025

Plus Therapeutics Announces New Employment Inducement Grants - The Manila Times

Mar 05, 2025
pulisher
Mar 05, 2025

Plus Therapeutics Awards 30,000 Stock Options to Newly Appointed CDOWhat's the Vesting Timeline? - StockTitan

Mar 05, 2025
pulisher
Mar 04, 2025

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

Plus Therapeutics Expects $15 Million in Gross Proceeds From Private Placement of Units; Shares Fall - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Plus Therapeutics tumbles on $15M private placement - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Plus Therapeutics sees $15M in gross proceeds from private placement - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Plus Therapeutics, Inc. Announces $15 Million Private Placement to Advance CNS Cancer Therapies - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Can Plus Therapeutics' $15M Financing Solve Its Nasdaq Delisting Challenge? - StockTitan

Mar 04, 2025
pulisher
Mar 03, 2025

Leptomeningeal Metastases Market Anticipated to Expand - openPR

Mar 03, 2025
pulisher
Mar 03, 2025

Understanding the Risks of Investing in Plus Therapeutics Inc (PSTV) - Knox Daily

Mar 03, 2025
pulisher
Mar 03, 2025

Glioma Treatment Market Size Report 2034 | AnHeart Therapeutics - openPR

Mar 03, 2025
$78.94
price up icon 2.53%
$318.85
price up icon 1.51%
$33.41
price up icon 0.00%
$20.11
price up icon 1.41%
$99.27
price up icon 0.31%
biotechnology ONC
$266.26
price up icon 1.87%
Cap:     |  Volume (24h):